I like the added interaction on this site… Background:
last week it was noted Oncy had/ has a relatively high % of short shares.
Blame who or what ever you want, excessive short sellling drives the SP. Down.
That was on the direct backs of the $15million bought deal @ 2.25 usd , holding warrants for about $2.61usd.
The SP, is obviously bellow that.
following the Q2 presentation, like always the covering analysts generated reports.
Target SP $3 to $15
Lots of associated data, etc etc.
the Q2 " update" did announce both good & bad for the short term SP.
Good, being most if the bought deal was an institutional investor. They went on to say, first time in their history a deal of that size....with that type of institution.
Good being, The discussion of additional pharma companies stepping up to show interest in using Pela alongside their product.
Good being, The detailed description of the PanCan trials arrangements.
They have in- place trail designs, FDA accepted protocols, many existing in place centres across the USA. Meaning no shortage of patients. Also, along that line which few appreciate. They can use exiting & on- going test patients as the control arm.
Reducing time & costs considerably.
Good being, they acknowledged that talkes are still underway for a phase 3 trial partner.
" creating a competitive environment "
Good/ bad..." they are in no rush to enter any agreement"
Updates?
seems like all the marbles. That we are made aware of...
resting on the upcoming conference this October ( bad for short term).
That update includes multiple data points. Most alongside Roche.
Bad bein The MBc trial entry & start up, information is a clear as mud.
They did not say it was stopped, nor did they indicate starting time. Other than the bracelet trial still has patients being followed.
THAT, is a huge unavoidable paradoxical situation. The longer life of the patients is great for Pela, those involved in the trial. However leads to a longer decision to start trial if O.S. Is being considered.
Meaning , could potentially be great news for ONC, however the delay is trouble for those waiting for something of substance.
Now what?
I did say, quite a while ago that Pancreatic cancer could leap frog over the .MBc in importance.
That picture will clarify October/ Nov of this year.
The longer term. ( more than next week for some lol ) ..looks very good.
The short term?
they did say a CAR-T deal could happen any time.
we are within a month of the " 90 day update".
buy- out?
not practical until after the awaited readouts in October.
anything is possible. Just not likely. With so much expected data from Goblet.
Additional good news from Panc or any others and the company rises considerably.
selling out now, would be a discount....based on doubt.
I like the depth of those posting on here. Most, with one exception discuss the company, directions, product. & business comparables.
The other; again check his profile.
look up Ad hominem attacks. Him to a T.
stock price short term?
like I said, the next run up will not be hindered by any ATM dillution.
looking forward to a reasonable short squeeze.
Buck Henry said he was tired of reading silly posts. Yet he keeps posting them.
Have a safe day, stay healthy & all the best.